Monopar Therapeutics (MNPR) Income from Continuing Operations (2017 - 2025)
Monopar Therapeutics (MNPR) reported Income from Continuing Operations of 4269637.0 for Q3 2025, down 189.36% on a YoY basis from 4778154.49 in Q3 2024, and down 65.64% sequentially from 2577616.0 in Q2 2025.
Monopar Therapeutics (MNPR) Income from Continuing Operations (2017 - 2025) Analysis & Trends
Monopar Therapeutics (MNPR) has 9 years of Income from Continuing Operations data on file, last reported at 4269637.0 in Q3 2025.
- For the quarter ending Q3 2025, Income from Continuing Operations fell 189.36% year-over-year to 4269637.0; the trailing twelve-month figure through Sep 2025 stood at 11544286.0 (down 66.83% YoY), and the FY2025 full-year result was 13716095.0, up 11.45% from the prior year.
- Income from Continuing Operations declined to 4269637.0 in Q3 2025, from 2577616.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 1475558.0 in Q3 2024 to a low of 13420480.0 in Q4 2022.
- A 5-year average of 3518655.59 and a median of 2459020.0 in 2021 frame the typical range for Income from Continuing Operations.
- Across the five-year window, Income from Continuing Operations surged 31.6% in 2024 and sank 189.36% in 2025, its largest moves.
- Tracing MNPR's Income from Continuing Operations over 5 years: stood at 10401402.0 in 2021, then fell by 29.03% to 13420480.0 in 2022, then soared by 85.44% to 1953734.0 in 2023, then gained by 24.47% to 1475558.0 in 2024, then slumped by 189.36% to 4269637.0 in 2025.
- Business Quant data shows MNPR's Income from Continuing Operations at 4269637.0 in Q3 2025, 2577616.0 in Q2 2025, and 3221475.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Monopar Therapeutics | 800.03 Mn | 738.20 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -4.27 Mn |
| Jun 30, 2025 | -2.58 Mn |
| Mar 31, 2025 | -3.22 Mn |
| Sep 30, 2024 | -1.48 Mn |
| Jun 30, 2024 | -1.79 Mn |
| Mar 31, 2024 | -1.70 Mn |
| Sep 30, 2023 | -1.95 Mn |
| Jun 30, 2023 | -2.35 Mn |
| Mar 31, 2023 | -2.49 Mn |
| Dec 31, 2022 | -13.42 Mn |
| Sep 30, 2022 | -2.41 Mn |
| Jun 30, 2022 | -2.85 Mn |
| Mar 31, 2022 | -2.46 Mn |
| Dec 31, 2021 | -10.40 Mn |
| Sep 30, 2021 | -2.46 Mn |
| Jun 30, 2021 | -2.09 Mn |
| Mar 31, 2021 | -1.89 Mn |
| Dec 31, 2020 | -7.48 Mn |
| Sep 30, 2020 | -1.65 Mn |
| Jun 30, 2020 | -1.46 Mn |